Serosep, Quidel Ink US Distribution Deal for GI Panel

 

Serosep Ltd, has announced the exclusive distribution of the EntericBio® Dx assay to the US market through Quidel Corporation. Quidel Corporation (Nasdaq: QDEL) is a California-based leading manufacturer of diagnostic healthcare solutions serving to enhance the health and well-being of people around the globe through the development of diagnostic solutions that can lead to improved patient outcomes and provide economic benefits to the healthcare system.

 

“Quidel is pleased to be able to offer EntericBio® Dx system, a rapid, high throughput, molecular system with a multiplex gastrointestinal panel, providing results within 3 hours direct from sample.” Quidel CEO Douglas C. Bryant said in a statement.

CEO of Serosep Dermot Scanlon announced “Serosep is very pleased to partner with Quidel, a company that shares the same values of commitment to customer service and support. These values have set Serosep apart from its competitors ensuring EntericBio is now the most widely used Gastrointestinal Molecular Diagnostic test both in Ireland and the UK. Serosep is hoping to replicate this success in the USA through its co-operation with Quidel.”

 

w.360dx.com/molecular-diagnostics/serosep-quidel-ink-us-distribution-deal-gi-panel#.XZyYX25FxPY